Duality Biotherapeutics, Inc. (HKG:9606)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
280.00
-1.80 (-0.64%)
Apr 28, 2026, 4:08 PM HKT
35.00%
Market Cap 25.45B
Revenue (ttm) 2.06B
Net Income (ttm) -2.89B
Shares Out 90.31M
EPS (ttm) -44.32
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 400,945
Average Volume 1,017,804
Open 281.80
Previous Close 281.80
Day's Range 277.00 - 292.00
52-Week Range 165.50 - 563.50
Beta n/a
RSI 41.38
Earnings Date Mar 23, 2026

About Duality Biotherapeutics

Duality Biotherapeutics, Inc., a clinical-stage biotech company, discovers and develops antibody-drug conjugate (ADC) therapeutics to treat cancer, autoimmune diseases, and others. The company provides DB-1303/BNT323, a HER2 ADC candidate targeting cancers, including endometrial cancer1 and breast cancer2; DB-1311/BNT324, a B7-H3 ADC candidate targeting cancers, such as small-cell lung cancer3, castration-resistant prostate cancer4, esophageal squamous cell carcinoma5, and head and neck squamous cell carcinoma; and other clinical-stage ADCs. It... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2019
Employees 231
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 9606
Full Company Profile

Financial Performance

In 2025, Duality Biotherapeutics's revenue was 1.85 billion, a decrease of -4.61% compared to the previous year's 1.94 billion. Losses were -2.59 billion, 147.0% more than in 2024.

Financial numbers in CNY Financial Statements

News

There is no news available yet.